{"id":77700,"date":"2022-05-25T11:11:16","date_gmt":"2022-05-25T09:11:16","guid":{"rendered":"https:\/\/www.csregypt.com\/?p=77700"},"modified":"2022-05-25T00:53:04","modified_gmt":"2022-05-24T22:53:04","slug":"19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine","status":"publish","type":"post","link":"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/","title":{"rendered":"$19.3 m allocated for developing ‘variant-proof’ SARS-CoV-2 vaccine"},"content":{"rendered":"

The University of Sydney<\/a> is a lead partner in an international consortium awarded up to $19.3 million by The Coalition for Epidemic Preparedness Innovations to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate.<\/p>\n

The multidisciplinary collaboration of Bharat Biotech International Ltd (Bharat Biotech), India, ExcellGene SA, Switzerland and the University of Sydney, Australia seeks to establish preclinical and clinical proof of concept for a protein subunit vaccine designed to provide broad protection against all known SARS-CoV-2 variants of concern, as well as future and yet to emerge variants of the virus.<\/p>\n

\u00a0The Coalition for Epidemic Preparedness Innovations (CEPI) is funding the researchers to conduct activities including immunogen design (to trigger a strong immune response), preclinical studies, manufacturing process development and a Phase 1 clinical trial.<\/p>\n

\u201cThe threat of a new variant emerging that might evade the protection of our current vaccines is real, so investing in R&D for variant-proof SARS-CoV-2 vaccines is a global health security imperative. Our partnership with Bharat Biotech, University of Sydney and ExcellGene will advance the development of a vaccine candidate to protect against future variants of COVID-19, potentially contributing to the long-term control of the virus,\u201d Dr Richard Hatchett, CEO of CEPI, said.<\/p>\n

Professor\u00a0Robyn Ward<\/a>, Executive Dean and Pro Vice-Chancellor Medicine and Health at the University said \u201cThe University is delighted to partner with CEPI to progress its platform for the development of broadly protective COVID-19 vaccines. Our researchers are at the medical forefront of tackling the COVID-19 pandemic, as well as anticipating what may lie ahead.\u201d<\/p>\n

Lead University of Sydney investigator Professor\u00a0Jamie Triccas<\/a>\u00a0said the collaboration aims to deliver safe, affordable and highly effective vaccines to combat existing and future SARS-CoV-2 variants.<\/p>\n

\u201cOur international consortium is well placed to achieve this goal. The University of Sydney will provide a framework for pre-clinical assessment of vaccine candidates, together with access to Australia\u2019s world-class early phase\u00a0clinical\u00a0trial\u00a0community,\u201d said Professor Triccas of the\u00a0Sydney Institute for Infectious Diseases<\/a>, Faculty of Medicine and Health.<\/p>\n

Co-Investigator Dr\u00a0Megan Steain<\/a>\u00a0said the work is important as we will continue to see high levels of circulating virus across the globe and the emergence of new variants with potential to evade pre-existing immunity.<\/p>\n

\u201cWe aim to create a vaccine that \u2018future proofs\u2019 us against SARS-CoV-2 variants or new betacoronaviruses that may enter the human population. In addition, the vaccine technology we are utilising will bolster the vaccine development landscape in NSW and Australia,\u201d said Dr Steain\u00a0<\/strong>of the Sydney Institute for Infectious Diseases and School of Medical Sciences.<\/p>\n","protected":false},"excerpt":{"rendered":"

The University of Sydney is a lead partner in an international consortium awarded up to $19.3 million by The Coalition for Epidemic Preparedness Innovations to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate. The multidisciplinary collaboration of Bharat Biotech International Ltd (Bharat Biotech), India, ExcellGene SA, Switzerland and the University of Sydney, Australia seeks […]<\/p>\n","protected":false},"author":410,"featured_media":77707,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6031,984],"tags":[],"yoast_head":"\n$19.3 m allocated for developing 'variant-proof' SARS-CoV-2 vaccine - Csr Egypt<\/title>\n<meta name=\"description\" content=\"The University of Sydney is a lead partner in an international consortium awarded up to $19.3 million by The Coalition for Epidemic Preparedness Innovations to support the development of a 'variant-proof' SARS-CoV-2 vaccine candidate.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"$19.3 m allocated for developing 'variant-proof' SARS-CoV-2 vaccine - Csr Egypt\" \/>\n<meta property=\"og:description\" content=\"The University of Sydney is a lead partner in an international consortium awarded up to $19.3 million by The Coalition for Epidemic Preparedness Innovations to support the development of a 'variant-proof' SARS-CoV-2 vaccine candidate.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/\" \/>\n<meta property=\"og:site_name\" content=\"Csr Egypt\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/csregypt\/\" \/>\n<meta property=\"article:published_time\" content=\"2022-05-25T09:11:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-05-24T22:53:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/05\/2-20261.png\" \/>\n\t<meta property=\"og:image:width\" content=\"567\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Marwa Zein\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@egyptcsrforum\" \/>\n<meta name=\"twitter:site\" content=\"@egyptcsrforum\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Marwa Zein\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/\"},\"author\":{\"name\":\"Marwa Zein\",\"@id\":\"https:\/\/csregypt.com\/#\/schema\/person\/5df2c73ec5c5eaada424a85f98cd7bec\"},\"headline\":\"$19.3 m allocated for developing ‘variant-proof’ SARS-CoV-2 vaccine\",\"datePublished\":\"2022-05-25T09:11:16+00:00\",\"dateModified\":\"2022-05-24T22:53:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/\"},\"wordCount\":429,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/csregypt.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/05\/2-20261.png\",\"articleSection\":[\"health\",\"news\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/\",\"url\":\"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/\",\"name\":\"$19.3 m allocated for developing 'variant-proof' SARS-CoV-2 vaccine - Csr Egypt\",\"isPartOf\":{\"@id\":\"https:\/\/csregypt.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/05\/2-20261.png\",\"datePublished\":\"2022-05-25T09:11:16+00:00\",\"dateModified\":\"2022-05-24T22:53:04+00:00\",\"description\":\"The University of Sydney is a lead partner in an international consortium awarded up to $19.3 million by The Coalition for Epidemic Preparedness Innovations to support the development of a 'variant-proof' SARS-CoV-2 vaccine candidate.\",\"breadcrumb\":{\"@id\":\"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/#primaryimage\",\"url\":\"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/05\/2-20261.png\",\"contentUrl\":\"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/05\/2-20261.png\",\"width\":567,\"height\":330,\"caption\":\"$19.3 m allocated for developing 'variant-proof' SARS-CoV-2 vaccine\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/csregypt.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"$19.3 m allocated for developing ‘variant-proof’ SARS-CoV-2 vaccine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/csregypt.com\/#website\",\"url\":\"https:\/\/csregypt.com\/\",\"name\":\"\u0633\u064a \u0625\u0633 \u0622\u0631 \u0645\u0635\u0631\",\"description\":\"The first portal for CSR in Egypt and Middle East\",\"publisher\":{\"@id\":\"https:\/\/csregypt.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/csregypt.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/csregypt.com\/#organization\",\"name\":\"CSR\",\"url\":\"https:\/\/csregypt.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/csregypt.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.csregypt.com\/wp-content\/uploads\/2019\/05\/logos-7.png\",\"contentUrl\":\"https:\/\/www.csregypt.com\/wp-content\/uploads\/2019\/05\/logos-7.png\",\"width\":1080,\"height\":1080,\"caption\":\"CSR\"},\"image\":{\"@id\":\"https:\/\/csregypt.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/csregypt\/\",\"https:\/\/x.com\/egyptcsrforum\",\"https:\/\/www.instagram.com\/csr.egypt\/\",\"https:\/\/www.linkedin.com\/in\/csr-egypt-43381ab5\/\",\"https:\/\/www.pinterest.com.au\/csregypt\/\",\"https:\/\/www.youtube.com\/channel\/UCh21PZpnBj2yjj2PeclXz1g\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/csregypt.com\/#\/schema\/person\/5df2c73ec5c5eaada424a85f98cd7bec\",\"name\":\"Marwa Zein\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/csregypt.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/383ed3b7c60ec18a972e284b402d1b29?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/383ed3b7c60ec18a972e284b402d1b29?s=96&d=mm&r=g\",\"caption\":\"Marwa Zein\"},\"sameAs\":[\"http:\/\/marwazein1982@gmail.com\"],\"url\":\"https:\/\/csregypt.com\/en\/author\/marwa-zein\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"$19.3 m allocated for developing 'variant-proof' SARS-CoV-2 vaccine - Csr Egypt","description":"The University of Sydney is a lead partner in an international consortium awarded up to $19.3 million by The Coalition for Epidemic Preparedness Innovations to support the development of a 'variant-proof' SARS-CoV-2 vaccine candidate.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/","og_locale":"en_US","og_type":"article","og_title":"$19.3 m allocated for developing 'variant-proof' SARS-CoV-2 vaccine - Csr Egypt","og_description":"The University of Sydney is a lead partner in an international consortium awarded up to $19.3 million by The Coalition for Epidemic Preparedness Innovations to support the development of a 'variant-proof' SARS-CoV-2 vaccine candidate.","og_url":"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/","og_site_name":"Csr Egypt","article_publisher":"https:\/\/www.facebook.com\/csregypt\/","article_published_time":"2022-05-25T09:11:16+00:00","article_modified_time":"2022-05-24T22:53:04+00:00","og_image":[{"width":567,"height":330,"url":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/05\/2-20261.png","type":"image\/png"}],"author":"Marwa Zein","twitter_card":"summary_large_image","twitter_creator":"@egyptcsrforum","twitter_site":"@egyptcsrforum","twitter_misc":{"Written by":"Marwa Zein","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/#article","isPartOf":{"@id":"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/"},"author":{"name":"Marwa Zein","@id":"https:\/\/csregypt.com\/#\/schema\/person\/5df2c73ec5c5eaada424a85f98cd7bec"},"headline":"$19.3 m allocated for developing ‘variant-proof’ SARS-CoV-2 vaccine","datePublished":"2022-05-25T09:11:16+00:00","dateModified":"2022-05-24T22:53:04+00:00","mainEntityOfPage":{"@id":"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/"},"wordCount":429,"commentCount":0,"publisher":{"@id":"https:\/\/csregypt.com\/#organization"},"image":{"@id":"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/05\/2-20261.png","articleSection":["health","news"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/","url":"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/","name":"$19.3 m allocated for developing 'variant-proof' SARS-CoV-2 vaccine - Csr Egypt","isPartOf":{"@id":"https:\/\/csregypt.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/#primaryimage"},"image":{"@id":"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/05\/2-20261.png","datePublished":"2022-05-25T09:11:16+00:00","dateModified":"2022-05-24T22:53:04+00:00","description":"The University of Sydney is a lead partner in an international consortium awarded up to $19.3 million by The Coalition for Epidemic Preparedness Innovations to support the development of a 'variant-proof' SARS-CoV-2 vaccine candidate.","breadcrumb":{"@id":"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/#primaryimage","url":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/05\/2-20261.png","contentUrl":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/05\/2-20261.png","width":567,"height":330,"caption":"$19.3 m allocated for developing 'variant-proof' SARS-CoV-2 vaccine"},{"@type":"BreadcrumbList","@id":"https:\/\/csregypt.com\/en\/19-3-m-allocated-for-developing-variant-proof-sars-cov-2-vaccine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/csregypt.com\/"},{"@type":"ListItem","position":2,"name":"$19.3 m allocated for developing ‘variant-proof’ SARS-CoV-2 vaccine"}]},{"@type":"WebSite","@id":"https:\/\/csregypt.com\/#website","url":"https:\/\/csregypt.com\/","name":"\u0633\u064a \u0625\u0633 \u0622\u0631 \u0645\u0635\u0631","description":"The first portal for CSR in Egypt and Middle East","publisher":{"@id":"https:\/\/csregypt.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/csregypt.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/csregypt.com\/#organization","name":"CSR","url":"https:\/\/csregypt.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/csregypt.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.csregypt.com\/wp-content\/uploads\/2019\/05\/logos-7.png","contentUrl":"https:\/\/www.csregypt.com\/wp-content\/uploads\/2019\/05\/logos-7.png","width":1080,"height":1080,"caption":"CSR"},"image":{"@id":"https:\/\/csregypt.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/csregypt\/","https:\/\/x.com\/egyptcsrforum","https:\/\/www.instagram.com\/csr.egypt\/","https:\/\/www.linkedin.com\/in\/csr-egypt-43381ab5\/","https:\/\/www.pinterest.com.au\/csregypt\/","https:\/\/www.youtube.com\/channel\/UCh21PZpnBj2yjj2PeclXz1g"]},{"@type":"Person","@id":"https:\/\/csregypt.com\/#\/schema\/person\/5df2c73ec5c5eaada424a85f98cd7bec","name":"Marwa Zein","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/csregypt.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/383ed3b7c60ec18a972e284b402d1b29?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/383ed3b7c60ec18a972e284b402d1b29?s=96&d=mm&r=g","caption":"Marwa Zein"},"sameAs":["http:\/\/marwazein1982@gmail.com"],"url":"https:\/\/csregypt.com\/en\/author\/marwa-zein\/"}]}},"jetpack_featured_media_url":"https:\/\/csregypt.com\/wp-content\/uploads\/2022\/05\/2-20261.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/posts\/77700"}],"collection":[{"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/users\/410"}],"replies":[{"embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/comments?post=77700"}],"version-history":[{"count":1,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/posts\/77700\/revisions"}],"predecessor-version":[{"id":77709,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/posts\/77700\/revisions\/77709"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/media\/77707"}],"wp:attachment":[{"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/media?parent=77700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/categories?post=77700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/csregypt.com\/en\/wp-json\/wp\/v2\/tags?post=77700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}